Exact Sciences (EXAS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

EXAS · Stock Price

USD 104.91+53.28 (+103.20%)

Market Cap: $20.0B

Historical price data

Market Cap: $20.0BPatents: 20Founded: 1995Employees: 5,000-10,000HQ: Madison, United States

Sector Ranking#25 in Diagnostics & Precision Medicine

Overview

Exact Sciences is a $20+ billion market cap leader in cancer diagnostics, driven by a mission to prevent, detect earlier, and guide treatment for cancer. Its success is anchored by the dominant Cologuard® colorectal cancer screening test and the globally recognized Oncotype DX® genomic test suite. The company's strategy focuses on expanding its integrated oncology portfolio, notably through the launch of its multi-cancer early detection test, CancerGuard™, and leveraging strategic partnerships like the one with Abbott for enhanced global scale. This positions Exact Sciences to address the full cancer care continuum from screening to treatment guidance.

Oncology

Technology Platform

A multi-modal platform integrating stool-based DNA (sDNA) testing, tissue-based genomic profiling, liquid biopsy/ctDNA analysis, and advanced bioinformatics to enable cancer screening, early detection, and therapy guidance across the care continuum.

Funding History

1

IPOUndisclosedUndisclosedJan 26, 2001

Opportunities

The multi-cancer early detection (MCED) market represents a transformative, $100+ billion global opportunity that could become the company's primary growth engine.

Additionally, expanding the use of minimal residual disease (MRD) monitoring in colorectal and other cancers offers a significant near-term growth vector within the precision oncology segment.

Risk Factors

Key risks include the clinical and regulatory uncertainty surrounding the pivotal studies for CancerGuard™ and the potential for unfavorable reimbursement decisions from Medicare and private payers.

The company also faces intense competition in both the MCED and therapy selection markets from well-capitalized rivals like GRAIL and Guardant Health.

Competitive Landscape

Exact Sciences competes in segmented markets: against colonoscopy and FIT tests in CRC screening; against Myriad, Agendia, and others in therapy selection; and against GRAIL (Galleri) and Guardant Health in the emerging MCED space. Its integrated portfolio and established commercial footprint are key differentiators.